LNP023
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary IgA Nephropathy
Conditions
Primary IgA Nephropathy
Trial Timeline
Sep 20, 2021 → Oct 25, 2032
NCT ID
NCT04557462About LNP023
LNP023 is a phase 3 stage product being developed by Novartis for Primary IgA Nephropathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04557462. Target conditions include Primary IgA Nephropathy.
What happened to similar drugs?
20 of 20 similar drugs in Primary IgA Nephropathy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06934967 | Phase 3 | Recruiting |
| NCT06931691 | Pre-clinical | Recruiting |
| NCT04557462 | Phase 3 | Recruiting |
| NCT03955445 | Phase 3 | Recruiting |
| NCT03896152 | Phase 2 | Completed |
| NCT03832114 | Phase 2 | Completed |
| NCT03373461 | Phase 2 | Completed |
Competing Products
20 competing products in Primary IgA Nephropathy